Journals / Journal of Experimental and Clinical Medicine / 2022 / Cilt: 39 - Sayı: 1

Compendium of polycystic ovarian syndrome and its relevance in glycation and diabetes

Pages
256–268
Publication Date
2022-01-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The current review also provides insights about usage of M. oleifera and S. platensis as a potential therapeutic agent for symptomatic relief of PCOS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Polycystic ovarian syndrome (PCOS) is one of the most common endocrine and reproductive disorders observed in women.
📊
Key Findings & Data:Its pathophysiology indicates its involvement in plenitude of diseases and/ or disorders.
💡
Conclusion & Impact:The current review also provides insights about usage of M. oleifera and S. platensis as a potential therapeutic agent for symptomatic relief of PCOS.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Altered steroidogenesis · Glycation · Insulin resistance

Abstract

Polycystic ovarian syndrome (PCOS) is one of the most common endocrine and reproductive disorders observed in women. Its pathophysiology indicates its involvement in plenitude of diseases and/ or disorders. Although the absolute cause of PCOS has not been established, its prevalence in diabetic patients is noteworthy. Glycation and insulin resistance being key factors in diabetes, the present review tries to study their correlation with PCOS. Amongst the available drugs, four commonly prescribed drugs namely, metformin, inositol, thiazolidinediones, and spironolactone have been discussed. The current review also provides insights about usage of M. oleifera and S. platensis as a potential therapeutic agent for symptomatic relief of PCOS.

🔖

Cite This Article

POOJARİ, P., PADGAONKAR, A., PARAMANYA, A., ALİ, A. (2022). Compendium of polycystic ovarian syndrome and its relevance in glycation and diabetes. Journal of Experimental and Clinical Medicine, Cilt: 39 - Sayı: 1, 256–268. https://ajindex.com/articles/677807

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Nestler J. Insulin regulation of human ovarian androgens. Hum Reprod. 12(suppl 1), 1997
  2. DOI: 10.1093/humrep/12.suppl_1.53 2. Schoemaker J. Neuroendocrine control in polycystic ovary-like syndrome. Gynec Endocrino. 1991
  3. 5(4), 277-288. DOI: 10.3109/09513599109028449 3. Diamanti-Kandarakis E & Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update. 2005
  4. 11(6), 631-643. DOI: 10.1093/humupd/dmi025 4. Xita N, Georgiou I, & Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol. 2002
  5. DOI: 10.1530/eje.0.1470717 5. Diamanti-Kandarakis E & Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. Endocrine Reviews. 2012
  6. 33(6), 981-1030. DOI: 10.1210/er.2011-1034 6. Diamanti-Kandarakis E & Dunaif A. PolyCystic Ovarian Syndrome: An Updated Overview. Front Physiol. 2012
  7. 7, 124. https://doi.org/10.3389/fphys.2016.00124 7. Bajuk Studen K & Pfeifer M. Cardiometabolic risk in polycystic ovary syndrome. Endocr Connect. 2018
  8. 7(7), R238-R251. DOI: 10.1530/ec-18-0129 8. Wang, F., Wang, S., Zhang, Z., Lin, Q., Liu, Y., & Xiao, Y. et al. Defective insulin signaling and the protective effects of dimethyldiguanide during follicular development in the ovaries of polycystic ovary syndrome. Mol Med Rep. 2017
  9. 16(6), 8164-8170. DOI: 10.3892/mmr.2017.7678 9. Dunaif A, Xia J, Book C, Schenker E & Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 1995
  10. 96 (2), 801-810. DOI: 10.1172/jci118126 10. Dunaif A, Segal K, Shelley D, Green G, Dobrjansky A & Licholai T. Evidence for distinctive and intrinsic defects in insulin action in Polycystic Ovary Syndrome. Diabetes. 1992
  11. 41(10), 1257-1266. DOI: 10.2337/diab.41.10.1257 11. Venkatesan A. Insulin Resistance in Polycystic Ovary Syndrome: Progress and Paradoxes. Recent Prog Horm Res. 2001
  12. 56(1), 295-308. DOI: 10.1210/rp.56.1.295 12. Sano H, Higashi T, Matsumoto K, Melkko J, Jinnouchi Y, & Ikeda K. et al. Insulin Enhances Macrophage Scavenger Receptor-mediated Endocytic Uptake of Advanced Glycation End Products. J Biol Chem. 1998
  13. 273(15), 8630-8637. DOI: 10.1074/jbc.273.15.8630 13. Diamanti-Kandarakis E, Piperi C, Kalofoutis A & Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrom